Entrada Therapeutics announced Phase 1/2 trial results showing only a 2.36% increase in dystrophin production, far below expectations for treating Duchenne muscular dystrophy. Despite calling the results "positive," the data led to a 57% drop in Entrada's stock price. Pomerantz LLP is now investigating whether Entrada and its executives engaged in securities fraud or unlawful practices. Investors affected by the stock decline are encouraged to contact the law firm for potential class action participation.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
